Emyria Eyes September Launch of First Sydney Clinic With Patients Already Approved

Emyria set to open first Sydney clinic as operational milestones land

Emyria Limited (ASX: EMD) has announced that preparations for its first Sydney clinic are on track, with the site expected to commence operations in September 2026. The opening will establish the company’s first presence in New South Wales, extending its clinical network into Australia’s largest population market.

With the fit-out complete and the clinical team in place, the key pre-launch milestones are now substantially established:

• Fit-out complete: Four dedicated treatment rooms furnished and equipped
• Clinical team trained: Approximately 20 Sydney-based therapists and 4 psychiatrists recruited and trained
• Authorised Prescribers in place: 2 Sydney psychiatrists have obtained TGA Authorised Prescriber status
• Healthcare partnerships secured: Formal agreement signed with Matilda Nepean Private Hospital
• Medication supply confirmed: Pharmacy and pharmaceutical arrangements in place
• First patients approved: Patients via the workers compensation pathway are expected to commence treatment shortly after opening

What the Sydney expansion means for Emyria’s national footprint

With operations already established across Queensland, Victoria, and Western Australia, New South Wales represents the fourth state in Emyria’s growing national clinical network. The Sydney clinic fills the most significant geographic gap in that network, providing access to specialist mental health care in the country’s most populous state.

A notable feature of the launch is that the first patient pipeline is already in place. Patients approved through the workers compensation pathway are expected to begin treatment shortly after the clinic opens, meaning the site is not starting from zero on day one.

The pre-launch foundations now secured include:

1. Clinical team recruited and trained, with Authorised Prescribers endorsed by the TGA
2. Formal institutional partnership with Matilda Nepean Private Hospital established
3. Pharmacy and pharmaceutical supply chain confirmed
4. First patient cohort approved ahead of opening

Sydney Clinic Launch Readiness Snapshot

Understanding psychedelic-assisted therapy — the treatment driving demand

Psychedelic-assisted therapy involves the supervised administration of substances such as MDMA or psilocybin in a controlled clinical setting, typically combined with psychological support before, during, and after each session. The approach is directed at patients who have not achieved adequate outcomes from conventional mental health treatments, including those with conditions such as PTSD and treatment-resistant depression.

PTSD remission outcomes from Emyria’s real-world patient cohort show 67% of treatment-resistant patients maintaining clinical remission 12 months or more after completing the programme, with a median time to remission of 28 days, data that underpins the commercial case for insurer and workers compensation funding across all network sites.

In Australia, the TGA Authorised Prescriber pathway allows approved psychiatrists to prescribe these medicines outside of a clinical trial setting, subject to individual patient assessment. Having 2 Authorised Prescribers in place before the Sydney clinic opens is a regulatory prerequisite, without which treatments cannot legally commence.

The sector is attracting increasing global capital and institutional attention. Eli Lilly’s acquisition of AtaiBeckley for approximately $3.8 billion and Johnson & Johnson leading an $85 million Series C investment in Delix Therapeutics reflect the scale of pharmaceutical industry interest in this category. Policy activity in the United States, including FDA initiatives aimed at accelerating access to emerging psychedelic-based treatments, adds further momentum. These developments involve third-party companies and are cited here to illustrate broader sector activity, not as Emyria’s own achievements.

What this means for Emyria investors

The Sydney launch arrives with a level of operational readiness that reduces the typical risks of a new clinic opening. The clinical team is trained, the prescribing framework is authorised, institutional partnerships are formalised, and a patient cohort is already approved. Taken together, these factors suggest the site is positioned to move to active patient treatment relatively quickly after the doors open.

Emyria now spans four Australian states, meaningfully expanding its addressable patient base and the depth of its national clinical infrastructure.

Greg Hutchinson, Executive Chairman

“Sydney represents an important expansion of Emyria’s national footprint and provides the Company with a presence in Australia’s largest population market. Importantly, it will create a new pathway for patients across New South Wales seeking access to specialist and evidence-based mental health treatments.”

The Sydney clinic is expected to function as a further building block in Emyria’s broader ambition to develop a national network of clinical sites and advance its treatment development programmes across mental health and select neurological conditions.

For investors exploring how the Sydney site contributes beyond direct patient revenue, our deep-dive into the Empax Global Partnership Program covers the capital-light, sponsor-funded model that layers high-margin clinical trial infrastructure services on top of the reimbursed treatment business, with North American sponsor Psyence Group already operational across the existing network.

Don’t Miss the Next Healthcare Breakout

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ investors who stay ahead of the market on stocks like this one. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.